Adaptimmune hires Rafael Amado as CMO and Adrian Rawcliffe as CFO

4 March 2015

Adaptimmune, a UK biotech company focused on using T-cell therapy to treat cancer and infectious disease, has appointed Rafael Amado as chief medical officer and Adrian Rawcliffe as chief financial officer.

Dr Amado is to lead Adaptimmune’s clinical strategy and be responsibility for the company’s clinical trials in the US and Europe under its strategic collaboration with GlaxoSmithKline (LSE: GSK), and will lead the development of the company’s pipeline of wholly-owned research programs. He previously served as senior vice president and head of oncology research and development at GlaxoSmithKline (LSE: GSK), which he joined in 2008.

Mr Rawcliffe will lead the company’s financial management and operations, including compliance and risk management. He also joins from GlaxoSmithKline (LSE: GSK) where he was senior vice president of finance of its North American pharma business.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK